Moxifloxacin Brown & Burk Uk (Moxifloxacin Hydrochloride)

Moxifloxacin belongs to the fluoroquinolone class and works by inhibiting bacterial DNA gyrase and topoisomerase IV. These enzymes are essential for DNA replication and transcription; their inhibition stops bacterial cell division, leading to rapid bactericidal activity against a broad range of eye‑infecting bacteria.

The dosage regimen for Moxifloxacin ophthalmic solution is determined by the prescribing eye‑care professional based on the severity of the infection, patient age, and response to therapy. The prescriber will specify the number of drops, frequency, and duration of treatment.

Safety data for ocular use of moxifloxacin during pregnancy or lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Moxifloxacin offers a broad spectrum of activity against both Gram‑positive and Gram‑negative ocular pathogens and provides high ocular tissue penetration. Compared with older fluoroquinolones such as ciprofloxacin, it often requires less frequent dosing and may retain activity against some resistant strains, though choice of therapy should follow local susceptibility patterns and physician judgment.

The ophthalmic solution should be stored at room temperature, preferably below 25 °C, in its original container. Protect the product from direct light and moisture, and keep the cap tightly closed when not in use. Do not freeze the solution.

The medication is applied as an eye drop. The prescriber will instruct the patient on the number of drops per eye, the frequency (e.g., twice daily), and the total duration of therapy. Patients should wash their hands before instillation and avoid contaminating the dropper tip.

Serious adverse events, although rare, include severe allergic reactions, corneal ulceration or thinning, sudden loss of vision, and systemic hypersensitivity such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience intense eye pain, worsening redness, swelling, or any signs of an allergic reaction.

The product should not be used by individuals with a known hypersensitivity to moxifloxacin, other fluoroquinolones, or any excipients in the formulation. It is also contraindicated for viral or fungal eye infections, as it lacks activity against these pathogens and may delay appropriate therapy.